Long-acting octreotide—a somatostatin analogue—does not increase survival for patients with advanced hepatocellular carcinoma, say European clinical trialists ( Hepatology 2007; 45: 9—15 ).

Somatostatin has activity against some endocrine and non-endocrine tumours, and about 40% of hepatocellular carcinomas express receptors for this hormone. A previous trial by Elias Kouroumalis and colleagues suggested a survival advantage for short-acting octreotide compared with best supportive care, but the drug ...